Aurora kinase inhibitor TAK-901, Purity ≥98%

Synonym: TAK-901; 934541-31-8; 5-(3-(Ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; TAK901; TAK 901; 5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-9H-pyrido[2,3-b]indole-7-carboxamide; DM9UIR23R7; Aurora kinase inhibitor

MDL: MFCD18782651
CAS Number: 934541-31-8
Compound CID: 16124208

Product Size

5 mg; 10 mg; 25 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

TAK-901, soluble in DMSO and insoluble in ethanol and water, is an Aurora kinase inhibitor that disrupts cell division processes. It targets c-Src, CLK2, Abl, Abl (T315I), ALK2, ALK5, AMPK, ARG, ARK5, AuroraA-TPX2, and AuroraB-INCENP.

Molecular Weight

504.6

Molecular Formula

C₂₈H₃₂N₄O₃S

Targets

c-Src: 1.3 nM; CLK2: <2.0 nM; Abl: 6.4 nM; Abl (T315I): 9.0 nM; ALK2: 13 nM; ALK5: 78 nM; AMPK: 46 nM; ARG: 5.6 nM; ARK5: 9.1 nM; AuroraA-TPX2: 21 nM; AuroraB-INCENP: 15 nM

Form

Lyophilized powder

Purity

≥98%

Solubility

DMSO: 95 mg/mL (188.25 mM); Water: Insoluble; Ethanol: Insoluble

Identity

Confirmed by NMR/HPLC/MS.

Applications

TAK-901 can be employed to understand the inhibition of Aurora kinase B in cancer treatment.